Economic Implication of Targeting Higher Trough Level with Extended Half-Life FVIII Prophylaxis
DOI:
https://doi.org/10.7175/fe.v27i1.1604Keywords:
Hemophilia A, Prophylaxis, rFVIII, pharmacokinetic , Health economicsAbstract
AIM: This analysis aimed to assess the annual International Unit (IU) consumption and costs of prophylaxis therapies with extended half-life recombinant FVIII (EHL-rFVIII), targeting a traditional trough level of 1% and the higher levels of 3% and 5% recommended by recent guidelines and expert consensus, using a theoretical pharmacokinetic model.
METHODS: A pharmacokinetic model was developed to calculate annual treatment IU consumption and costs of EHL-rFVIII products to sustain different trough levels (1%, 3% and 5%) in adult patients with hemophilia A in Italy. The model assumed a one-year perspective and assessed two scenarios: one with lower frequency of administration and one with higher frequency.
RESULTS: The related annual treatment per-patient cost increased as the trough level increased. The per-patient annual cost was €117,811 to achieve a trough level of 1%, €351,543 to achieve a 3% trough level and €585,905 to achieve a 5% trough level. The increase in dose frequency (alternative scenario), that is the reduction of time between infusions, reduced the estimated doses to achieve the pre-defined FVIII levels.
CONCLUSIONS: These results suggest the need for further discussion about the trough levels to target with the actual EHL-rFVIII and the prophylaxis dose and regimen selection for each patient, also considering all treatment options available and the economic implications.
Additional Files
Published
Issue
Section
License
Copyright (c) 2026 Carla Fornari, Stefania Antonacci, Stefano Stoppa, Lorenzo Giovanni Mantovani, Giancarlo Castaman, Paolo Angelo Cortesi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
